Dr. Mihran H. Shirinian, MD

Dr. Shirinian practices at Adventist Health Glendale in Glendale, California, part of Adventist Health.

Dr. Shirinian's NPI, 1730262122, was assigned on October 23, 2006. Dr. Shirinian graduated from OHSU School of Medicine in 1980. Dr. Shirinian holds California license 954404203.

Dr. Shirinian's primary practice is Adventist Health Glendale, at 1509 E Wilson Terrace, Glendale, CA 91206 in Los Angeles County. The practice phone is (818) 409-8202.

Dr. Shirinian's primary practice is Adventist Health Glendale in Glendale, California, part of Adventist Health. Dr. Shirinian is also affiliated with USC Verdugo Hills Hospital. The medical group on file is Comprehensive Hematology Oncology Centers. Dmand AI also links Dr. Shirinian to 1 more hospital, 1 group practice or clinic and 1 other site, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Shirinian practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Shirinian's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Shirinian is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Shirinian's licenses on file in 3 states: California, Texas and Illinois.

Dmand AI lists breast cancer, chronic anemia, chronic embolism thrombosis, chronic leukemia, colorectal cancer, deep vein thrombosis (DVT), fluid and electrolyte imbalances and lung cancer among the conditions Dr. Shirinian treats.

CMS data shows 186,318 Medicare services from Dr. Shirinian across 41 procedure codes in 2024, for 805 Medicare patients. Medicare paid $1,285,548 for them.

CMS counts 805 Medicare patients who saw Dr. Shirinian in 2024. The largest group is 75 to 84, with 308 patients. 75% of them have arthritis, and 75% have high blood pressure. 76% are also on Medicaid. Their average risk score is 2.31, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Shirinian's median patient age at 75, with 62% women.

In 2024, Dr. Shirinian wrote 2,733 Medicare Part D claims for 256 patients. 57% of them were for generic drugs. CMS names the drug for 2,397 of them, across 54 drugs with 11 or more claims each, at $9,750,344 in total drug cost. In 2023, CMS named 2,848 claims across 59 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Shirinian for performance year 2024, reported individually. Dr. Shirinian accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Shirinian as offering telehealth.

Dmand AI links 8 papers to Dr. Shirinian. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Squamous Cell and Cisplatin. Dr. Shirinian has published most often in Am J Clin Oncol. Dr. Shirinian's most frequent co-authors are Adam S. Garden, MD and Paul Y. Holoye, MD.

Dmand AI links Dr. Shirinian to 4 clinical trials, 2 of them phase 3 studies. 3 are still active or recruiting. Conditions studied include Breast Neoplasms, Carcinoma, Neuroendocrine and Carcinoma, Non-Small-Cell Lung. ImmunityBio, Inc. sponsors the most, 2.

CMS Open Payments shows 190 general payments to Dr. Shirinian from 33 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 53% of the total. Genentech, Inc. paid the most, $10,791. It also lists 2 research payments totaling $2,428 from 2016 to 2017.

Dr. Shirinian graduated from OHSU School of Medicine in 1980.

Dr. Shirinian is in network with 16 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.